193 related articles for article (PubMed ID: 37183242)
21. Respiratory syncytial virus immunization program for the United States: impact of performance determinants of a theoretical vaccine.
Régnier SA
Vaccine; 2013 Sep; 31(40):4347-54. PubMed ID: 23896421
[TBL] [Abstract][Full Text] [Related]
22. Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.
Treskova M; Pozo-Martin F; Scholz S; Schönfeld V; Wichmann O; Harder T
Pharmacoeconomics; 2021 Mar; 39(3):287-315. PubMed ID: 33462760
[TBL] [Abstract][Full Text] [Related]
23. Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25-26 April 2016.
Giersing BK; Karron RA; Vekemans J; Kaslow DC; Moorthy VS
Vaccine; 2019 Nov; 37(50):7355-7362. PubMed ID: 28302410
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
Li X; Bilcke J; Vázquez Fernández L; Bont L; Willem L; Wisløff T; Jit M; Beutels P;
J Infect Dis; 2022 Aug; 226(Suppl 1):S95-S101. PubMed ID: 35292816
[TBL] [Abstract][Full Text] [Related]
25. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis.
Li Y; Wang X; Blau DM; Caballero MT; Feikin DR; Gill CJ; Madhi SA; Omer SB; Simões EAF; Campbell H; Pariente AB; Bardach D; Bassat Q; Casalegno JS; Chakhunashvili G; Crawford N; Danilenko D; Do LAH; Echavarria M; Gentile A; Gordon A; Heikkinen T; Huang QS; Jullien S; Krishnan A; Lopez EL; Markić J; Mira-Iglesias A; Moore HC; Moyes J; Mwananyanda L; Nokes DJ; Noordeen F; Obodai E; Palani N; Romero C; Salimi V; Satav A; Seo E; Shchomak Z; Singleton R; Stolyarov K; Stoszek SK; von Gottberg A; Wurzel D; Yoshida LM; Yung CF; Zar HJ; ; Nair H;
Lancet; 2022 May; 399(10340):2047-2064. PubMed ID: 35598608
[TBL] [Abstract][Full Text] [Related]
26. Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand.
Prasad N; Read JM; Jewell C; Waite B; Trenholme AA; Huang QS; Grant CC; Newbern EC; Hogan AB
Vaccine; 2021 Jul; 39(31):4383-4390. PubMed ID: 34147296
[TBL] [Abstract][Full Text] [Related]
27. Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022.
Fitzpatrick MC; Laufer RS; Baral R; Driscoll AJ; Feikin DR; Fleming JA; Jit M; Kim S; Koltai M; Li Y; Li X; Nair H; Neuzil KM; Pecenka C; Sparrow E; Srikantiah P; Ortiz JR
Vaccine; 2023 Nov; 41(48):7047-7059. PubMed ID: 37777450
[TBL] [Abstract][Full Text] [Related]
28. Respiratory syncytial virus in infants: is maternal vaccination a realistic strategy?
Munoz FM
Curr Opin Infect Dis; 2015 Jun; 28(3):221-4. PubMed ID: 25918956
[TBL] [Abstract][Full Text] [Related]
29. WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.
Sparrow E; Adetifa I; Chaiyakunapruk N; Cherian T; Fell DB; Graham BS; Innis B; Kaslow DC; Karron RA; Nair H; Neuzil KM; Saha S; Smith PG; Srikantiah P; Were F; Zar HJ; Feikin D
Vaccine; 2022 Jun; 40(26):3506-3510. PubMed ID: 35184927
[TBL] [Abstract][Full Text] [Related]
30. Challenges in the prevention or treatment of RSV with emerging new agents in children from low- and middle-income countries.
Carbonell-Estrany X; Rodgers-Gray BS; Paes B
Expert Rev Anti Infect Ther; 2021 Apr; 19(4):419-441. PubMed ID: 32972198
[TBL] [Abstract][Full Text] [Related]
31. Lessons learned from COVID-19 vaccine acceptance among pregnant and lactating women from two districts in Kenya to inform demand generation efforts for future maternal RSV vaccines.
Limaye RJ; Singh P; Fesshaye B; Karron RA
BMC Pregnancy Childbirth; 2024 Mar; 24(1):221. PubMed ID: 38539077
[TBL] [Abstract][Full Text] [Related]
32. WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015.
Modjarrad K; Giersing B; Kaslow DC; Smith PG; Moorthy VS;
Vaccine; 2016 Jan; 34(2):190-197. PubMed ID: 26100926
[TBL] [Abstract][Full Text] [Related]
33. Clinical and epidemiologic features of respiratory syncytial virus.
Hall CB; Simőes EA; Anderson LJ
Curr Top Microbiol Immunol; 2013; 372():39-57. PubMed ID: 24362683
[TBL] [Abstract][Full Text] [Related]
34. Challenges in Maximizing Impacts of Preventive Strategies against Respiratory Syncytial Virus (RSV) Disease in Young Children.
Zheng Z
Yale J Biol Med; 2022 Jun; 95(2):293-300. PubMed ID: 35782467
[TBL] [Abstract][Full Text] [Related]
35. Respiratory syncytial virus circulation in seven countries with Global Disease Detection Regional Centers.
Haynes AK; Manangan AP; Iwane MK; Sturm-Ramirez K; Homaira N; Brooks WA; Luby S; Rahman M; Klena JD; Zhang Y; Yu H; Zhan F; Dueger E; Mansour AM; Azazzy N; McCracken JP; Bryan JP; Lopez MR; Burton DC; Bigogo G; Breiman RF; Feikin DR; Njenga K; Montgomery J; Cohen AL; Moyes J; Pretorius M; Cohen C; Venter M; Chittaganpitch M; Thamthitiwat S; Sawatwong P; Baggett HC; Luber G; Gerber SI
J Infect Dis; 2013 Dec; 208 Suppl 3():S246-54. PubMed ID: 24265484
[TBL] [Abstract][Full Text] [Related]
36. Respiratory syncytial virus infection and the need for immunization in Korea.
Kim HY; Yun KW; Cheong HJ; Choi EH; Lee HJ
Expert Rev Vaccines; 2023; 22(1):327-340. PubMed ID: 36960592
[TBL] [Abstract][Full Text] [Related]
37. Correlates of Protection Against Respiratory Syncytial Virus Infection in Infancy.
Abu-Raya B; Reicherz F; Lavoie PM
Clin Rev Allergy Immunol; 2022 Dec; 63(3):371-380. PubMed ID: 35689745
[TBL] [Abstract][Full Text] [Related]
38. Parental knowledge about respiratory syncytial virus (RSV) and attitudes to infant immunization with monoclonal antibodies.
Lee Mortensen G; Harrod-Lui K
Expert Rev Vaccines; 2022 Oct; 21(10):1523-1531. PubMed ID: 35929971
[TBL] [Abstract][Full Text] [Related]
39. Health care costs of hospitalization of young children for respiratory syncytial virus infections: a population-based matched cohort study.
Thampi N; Knight BD; Thavorn K; Webster RJ; Lanctot K; Hawken S; McNally JD
CMAJ Open; 2021; 9(4):E948-E956. PubMed ID: 34667075
[TBL] [Abstract][Full Text] [Related]
40. Evaluating vaccination strategies for reducing infant respiratory syncytial virus infection in low-income settings.
Poletti P; Merler S; Ajelli M; Manfredi P; Munywoki PK; Nokes D; Melegaro A
BMC Med; 2015 Mar; 13():49. PubMed ID: 25857701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
